Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (November 2006)

25 slides from Pharmacopeia's investor presentation, Nov 6, 2006

  1. Slide 1: Discovering excellence, driving clinical success

    Slide 1: Discovering excellence, driving clinical success

    Leslie J. Browne President & CEO November 6th, 2006 Discovering excellence, driving clinical success TM

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

  3. Slide 3: Value Drivers - Balanced Risk

    Slide 3: Value Drivers - Balanced Risk

    Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Leader in developing DARA – IND in 1Q-07 First-in-class dual-acting ARB and endothelin antagonists for kidney disease Deep pipeline of potential blockbusters 4 compounds in active clinical de

  4. Slide 4: Balancing Risk to Build Value

    Slide 4: Balancing Risk to Build Value

    Balancing Risk to Build Value 8 Million Compound Library Largest in the Industry Integrated HTS Medicinal Chemistry Pharmacology Development GSK Cephalon Organon Schering-Plough Bristol-Myers Squibb Unique Discovery Platform Strategic Partnerships Proprietary Programs High Value Portfolio Pharmacope

  5. Slide 5: Agenda for Today

    Slide 5: Agenda for Today

    Agenda for Today Strong sustainable pipeline p38 kinase inhibitors and CXCR2 antagonist approaching Phase II DARA properties and clinical development schedule Strong strategic partnerships Clinical development partners GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong funda

  6. Slide 6: One of the Deepest Portfolios in Biotech

    Slide 6: One of the Deepest Portfolios in Biotech

    Angiogenesis a v b 3 / a v b 5 PS388023 Parkinsons Adenosine A 2A PS246518 Rheumatoid/MS CCR1 PS375179 Transplantation JAK3 PS608504 Inflammation PS873266 Respiratory PS948115 Metabolic Disease PS522501 Inflammation PS386113 Oncology PS241541 CNS PS778629 Cardiovascular DARA PS433540 Oncology PS0957

  7. Slide 7: Partnered Pipeline Advancing

    Slide 7: Partnered Pipeline Advancing

    Partnered Pipeline Advancing Partnered clinical programs approaching Phase II p38 kinase inhibitors for RA Well tolerated in multiple Phase I trials Currently in RA patients receiving methotrexate Back up compound entered Phase I in December 2005 CXCR2 antagonist for COPD Active against biomarker at

  8. Slide 8: Dual Acting Angiotensin and Endothelin Receptor Antagonist (DARA)

    Slide 8: Dual Acting Angiotensin and Endothelin Receptor Antagonist (DARA)

    End Organ Disease Modification Dual Acting Angiotensin and Endothelin Receptor Antagonist (DARA) Resistant Hypertensions and Chronic Renal Disease Potentially control hypertension and fibrosis associated with loss of renal function pre- and post-transplant

  9. Slide 9: DARA – First-in-class

    Slide 9: DARA – First-in-class

    DARA – First-in-class Combines the properties of two marketed cardiovascular product classes in a single molecule Selectively blocks Angiotensin (ARB) and Endothelin (ERA) Strong preclinical and clinical data Patent protection at least to 2019 Potential in resistant hypertension and chronic kidney d

  10. Slide 10: Chronic Kidney Disease – Medical Need

    Slide 10: Chronic Kidney Disease – Medical Need

    Chronic Kidney Disease – Medical Need Progressive disease leading to dialysis and transplant 20 million in US suffer from chronic kidney disease 5% of US population suffers from diabetic nephropathy $17B potential addressable market in 2010 Underlying disease causes Diabetes Hypertension Obesity Glo

  11. Slide 11: Chronic Kidney Disease – Current Rx

    Slide 11: Chronic Kidney Disease – Current Rx

    Chronic Kidney Disease – Current Rx Angiotensin Receptor Blockers Approved Avapro® (irbesartan) and Cozaar® (losartan) ACE Inhihitors recommended Compounds Under Clinical Investigation Ph III Diabetic Nephropathy Sulodexide TM glycosaminoglycan components Keryx Ph II Diabetic Kidney Disease XL784 Ad

  12. Slide 12: Angiotensin II and Endothelin I

    Slide 12: Angiotensin II and Endothelin I

    Angiotensin II and Endothelin I Vasoconstriction Tissue proliferation and fibrosis Inflammation Preclinical Results Potent blockade of endothelin and angiotensin by oral route Potent BP lowering in predictive hypertension models (SHR and DOCA) Clinical Results – Diabetic nephropathy Improved renal h

  13. Slide 13: Dual Acting Receptor Antagonist PS433540

    Slide 13: Dual Acting Receptor Antagonist PS433540

    Dual Acting Receptor Antagonist 12 3 PS433540 1.4 > 10,000 BMS-19384 > 10,000 2 Irbesartan Endothelin IC 50 (nm, human) Angiotensin IC 50 (nm, human) Compound Irbesartan(Avapro®) AT 1 antagonist PS433540 (DARA) AT 1 and ET A antagonist BMS-193884 ET A antagonist Angiotensin group Endothelin group N

  14. Slide 14: Angiotensin and Endothelin Blockade

    Slide 14: Angiotensin and Endothelin Blockade

    Angiotensin and Endothelin Blockade Angiotensin II PS433540 blocks both angiotensin and endothelin in vivo after oral administration in rodents with ED 50 = 0.9, 7.6 mpk PS433540 Study PCO-NC-003 October 17, 2006 ED 50 = 0.9 mg/kg Vehicle-adjusted % Inhibition (normalized) 0 10 20 30 40 50 60 70 80

  15. Slide 15: PS433540 – Antihypertensive Activity

    Slide 15: PS433540 – Antihypertensive Activity

    PS433540 reduces blood pressure more than Irbesartan (Avapro) at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity PS433540

  16. Slide 16: Potential Treatment of Choice in Kidney Disease

    Slide 16: Potential Treatment of Choice in Kidney Disease

    Current Treatment of Renal Disease Unsatisfactory Disease progresses to dialysis and transplant despite treatment Impaired quality of life with high morbidity and mortality Emerging paradigm for better disease management ARBs approved for diabetic nephropathy Benefit demonstrated for investigational

  17. Slide 17: DARA Development Schedule

    Slide 17: DARA Development Schedule

    DARA Development Schedule Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 3Q-06 File IND 1Q-07 ‘First in man’ dosing 1Q-07 Initiate Phase Ib hypertension study End-07 Initiate Ph II 2H-08

  18. Slide 18: Phase I Clinical Evaluation

    Slide 18: Phase I Clinical Evaluation

    Phase I Clinical Evaluation Phase Ia in Healthy Subjects Establish Safety SAD (Single Ascending Dose) – up to 7 dose levels MAD (Multiple Ascending Dose) – up to 4 dose levels Confirm Dual Activity Mechanism Angiotensin Challenge in Healthy Volunteers Endothelin Challenge in Healthy Volunteers Phase

  19. Slide 19: Agenda for Today

    Slide 19: Agenda for Today

    Agenda for Today Strong sustainable pipeline p38 kinase inhibitors and CXCR2 antagonist approaching Phase II DARA properties and clinical development schedule Strong strategic partnerships Clinical development partners GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong funda

  20. Slide 20: Strategic Partnerships

    Slide 20: Strategic Partnerships

    Strategic Partnerships Late stage optimization programs Upfront $15 million technology access fee Up to $35 million per program in milestones Double-digit royalties Builds portfolio and financial runway Pharmacopeia prosecutes Phase I and Phase II Non-dilutive tranched funding - $15 million Up to $8

  21. Slide 21: Agenda for Today

    Slide 21: Agenda for Today

    Agenda for Today Strong sustainable pipeline p38 kinase inhibitors and CXCR2 antagonist approaching Phase II DARA properties and clinical development schedule Strong strategic partnerships Clinical development partners GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong funda

  22. Slide 22: Financial Summary

    Slide 22: Financial Summary

    Financial Summary For the 9 Months Ended September 30, 2006 $13.7 million in net revenue $19.6 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $30.4 million as of December 31 st , 2005 $31.0 million as of September 30, 2006 Received $20 m

  23. Slide 23: Stock Information

    Slide 23: Stock Information

    Stock Information Stock Exchange: NASDAQ Stock Symbol: PCOP Shares Outstanding (10/31/2006): 21.1 million 52- Week Range: $3.03 - $6.51 Market Capitalization (10/31/2006): ~ $95 million Enterprise Value*: ~ $40 million *Calculated on cash and liquid investments as of 09/30/2006 and financing proceed

  24. Slide 24: Pharmacopeia Today

    Slide 24: Pharmacopeia Today

    Pharmacopeia Today IND in Q1-07- first-in-class approach to significant markets Diabetic Nephropathy Resistant Hypertensions Clinical programs approaching Phase II p38 kinase inhibitor for RA (partnered with Bristol-Myers Squibb) CXCR2 antagonist for COPD (partnered with Schering-Plough) Portfolio o

  25. Slide 25: Discovering excellence, driving clinical success

    Slide 25: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical success TM

Source: SEC EDGAR · 8-K filed Nov 6, 2006

More decks from Pharmacopeia Inc